Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.
Yimeng GaoHong-Zhong JinPublished in: Dermatologic therapy (2021)
Rivaroxaban is a direct inhibitor of activated coagulation factor X and competitively targets factor Xa via reversible binding. We conducted a systematic review of the efficacy and safety of rivaroxaban for treatment of livedoid vasculopathy (LV) by searching the PubMed, Cochrane and Embase databases. A total of 22 articles and 1 registered clinical trial were identified in the search of which 13 were included. The studies included 73 LV patients receiving rivaroxaban therapy (10-20 mg per day). Overall, 60 patients (82.2%) had responses to therapy, achieving remission of both pain and ulceration. Few adverse effects were observed. Thus, the consensus of the clinical evidence is that rivaroxaban is a well-tolerated and effective treatment for LV. However, this still needs to be confirmed by large prospective and/or case control studies.
Keyphrases
- venous thromboembolism
- atrial fibrillation
- case control
- pulmonary embolism
- clinical trial
- end stage renal disease
- randomized controlled trial
- chronic pain
- newly diagnosed
- mesenchymal stem cells
- spinal cord injury
- open label
- neuropathic pain
- deep learning
- transcription factor
- spinal cord
- bone marrow
- postoperative pain